ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
9 hedge funds and large institutions have $14.5M invested in ESSA Pharma in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
63.04% more ownership
Funds ownership: 3.31% → 66.34% (+63%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $15.3M → $14.5M (-$744K)
18% less funds holding
Funds holding: 11 → 9 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$163K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$127K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$748 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$561 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$146 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$219K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3K |
| 5 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$4 |
EPIX Hedge Fund Activity: Q2 2018 in Review
9 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2018, worth a combined $14.5M — down 4.9% from $15.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EPIX and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was BVF Inc, adding an estimated $163K. The largest seller was CVI Holdings, exiting entirely with an estimated $219K sold.
- 9 institutional investors held ESSA Pharma (EPIX) as of Q2 2018, down from 11 in Q1 2018.
- Funds reported $14.5M of ESSA Pharma stock for Q2 2018, down 4.9% quarter-over-quarter.
- 3 funds opened new ESSA Pharma positions in Q2 2018 and 5 closed out, a net change of -2 holders.
- The largest ESSA Pharma buyer in Q2 2018 was BVF Inc, an estimated $163K added.
- The largest ESSA Pharma seller in Q2 2018 was CVI Holdings, an estimated $219K sold.
Based on aggregated 13F filings for Q2 2018.